{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:00Z","timestamp":1787020140118,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of the present study was to evaluate the association between the histology of active and chronic lesions and urinary protein and serum creatinine (SCr) levels, as common clinical endpoints in clinical trials for lupus nephritis (LN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In total, 119 patients diagnosed with LN class III, IV, and V, as defined by the International Society of Nephrology\/Renal Pathology Society, between 1990 and 2015, were enrolled in the present study. Multiple regression analysis was performed to explore semi-quantitative histological variables associated with urinary protein and SCr levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age of the enrolled patients was 45\u2009years, and 79% were female. The mean SCr and mean urinary protein levels at the time of renal biopsy were 0.87\u2009mg\/dl and 3.00\u2009g\/gCr, respectively. Class IV (71%) was the most common type of LN followed by class III (17%), and class V (13%). Multicollinearity was confirmed between monocellular infiltration (variance inflation factor [VIF]\u2009=\u200910.22) and interstitial fibrosis (VIF\u2009=\u200910.29), and between karyorrhexis (VIF\u2009=\u20094.14) and fibrinoid necrosis (VIF\u2009=\u20094.29). Fibrinoid necrosis and monocellular infiltration were subsequently excluded, and multiple regression analysis revealed that only the urinary protein level was correlated with wire loop lesions (\u03b2-coefficient [\u03b2]: 1.09 and confidence interval [CI]: 0.35 to 1.83), and that the SCr level was correlated with glomerular sclerosis (\u03b2: 1.08 and CI: 0.43 to 1.74).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>As urinary protein and SCr levels were not quantitatively associated with active lesions, they may not accurately reflect the response to remission induction therapy in patients with LN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-020-01868-9","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T12:03:55Z","timestamp":1591099435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of explanatory histological findings and urinary protein and serum creatinine levels at renal biopsy in lupus nephritis: a cross-sectional study"],"prefix":"10.1186","volume":"21","author":[{"given":"Eri","family":"Katsuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshia","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-0818","authenticated-orcid":false,"given":"Ken-ei","family":"Sada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumie","family":"Hiramatsu-Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Katsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Narazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"issue":"9","key":"1868_CR1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/14712598.2018.1504918","volume":"18","author":"Z Hruskova","year":"2018","unstructured":"Hruskova Z, Tesar V. Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. Expert Opin Biol Ther. 2018;18(9):989\u201396.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1868_CR2","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/lupus-2017-000239","volume":"4","author":"Z Touma","year":"2017","unstructured":"Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med. 2017;4(1):e000239.","journal-title":"Lupus Sci Med"},{"key":"1868_CR3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13075-015-0621-6","volume":"17","author":"KM Corapi","year":"2015","unstructured":"Corapi KM, Dooley MA, Pendergraft WF 3rd. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther. 2015;17:110.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1868_CR4","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/ndt\/gfv381","volume":"31","author":"LF Quintana","year":"2016","unstructured":"Quintana LF, Jayne D. Sustained remission in lupus nephritis: still a hard road ahead. Nephrol Dial Transplant. 2016;31(12):2011\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1868_CR5","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","volume":"67","author":"M Dall'Era","year":"2015","unstructured":"Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the euro-lupus nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305\u201313.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1868_CR6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1440-1797.2010.01290.x","volume":"15","author":"OE Ayodele","year":"2010","unstructured":"Ayodele OE, Okpechi IG, Swanepoel CR. Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology (Carlton). 2010;15(4):482\u201390.","journal-title":"Nephrology (Carlton)"},{"issue":"12","key":"1868_CR7","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ki.2009.344","volume":"76","author":"DM Fine","year":"2009","unstructured":"Fine DM, Ziegenbein M, Petri M, Han EC, McKinley AM, Chellini JW, Nagaraja HN, Carson KA, Rovin BH. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int. 2009;76(12):1284\u20138.","journal-title":"Kidney Int"},{"issue":"7","key":"1868_CR8","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/ard.2009.117200","volume":"69","author":"M Mosca","year":"2010","unstructured":"Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, Cervera R, Doria A, Jayne D, Khamashta MA, et al. European league against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"1868_CR9","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"343","author":"TM Chan","year":"2000","unstructured":"Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou nephrology study group. N Engl J Med. 2000;343(16):1156\u201362.","journal-title":"N Engl J Med"},{"issue":"2","key":"1868_CR10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","volume":"66","author":"R Furie","year":"2014","unstructured":"Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, Hillson JL, Meadows-Shropshire S, Kinaszczuk M, Merrill JT. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379\u201389.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1868_CR11","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1177\/0961203318776109","volume":"27","author":"B Obrisca","year":"2018","unstructured":"Obrisca B, Jurubita R, Andronesi A, Sorohan B, Achim C, Bobeica R, Gherghiceanu M, Mandache E, Ismail G. Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scoring of glomerular lesions. Lupus. 2018;27(9):1455\u201363.","journal-title":"Lupus"},{"issue":"6","key":"1868_CR12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/1756-185X.12059","volume":"16","author":"Z Shariati-Sarabi","year":"2013","unstructured":"Shariati-Sarabi Z, Ranjbar A, Monzavi SM, Esmaily H, Farzadnia M, Zeraati AA. Analysis of clinicopathologic correlations in Iranian patients with lupus nephritis. Int J Rheum Dis. 2013;16(6):731\u20138.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"1868_CR13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5694\/mja11.11468","volume":"197","author":"DW Johnson","year":"2012","unstructured":"Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Doogue MP, Jose MD, Langham RG, Lawton PD, McTaggart SJ, Peake MJ, et al. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust. 2012;197(4):224\u20135.","journal-title":"Med J Aust"},{"issue":"9","key":"1868_CR14","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1868_CR15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","volume":"65","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521\u201330.","journal-title":"Kidney Int"},{"issue":"6","key":"1868_CR16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"1868_CR17","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3899\/jrheum.080793","volume":"36","author":"S Kojo","year":"2009","unstructured":"Kojo S, Sada KE, Kobayashi M, Maruyama M, Maeshima Y, Sugiyama H, Makino H. Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis. J Rheumatol. 2009;36(10):2218\u201323.","journal-title":"J Rheumatol"},{"key":"1868_CR18","first-page":"48","volume":"24","author":"JC Fox","year":"1992","unstructured":"Fox JC, Prise KM. DNA lesions: linear energy transfer and radiosensitive mutants. BJR Suppl. 1992;24:48\u201352.","journal-title":"BJR Suppl"},{"issue":"2","key":"1868_CR19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/019394599001200204","volume":"12","author":"MA Schroeder","year":"1990","unstructured":"Schroeder MA. Diagnosing and dealing with multicollinearity. West J Nurs Res. 1990;12(2):175\u201384 discussion 184-177.","journal-title":"West J Nurs Res"},{"issue":"4","key":"1868_CR20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000045424","volume":"83","author":"A Hurtado","year":"1999","unstructured":"Hurtado A, Asato C, Escudero E, Stromquist CS, Urcia J, Hurtado ME, de La Cruz S, Wener MH, Zavala R, Johnson RJ. Clinicopathologic correlations in lupus nephritis in Lima, Peru. Nephron. 1999;83(4):323\u201330.","journal-title":"Nephron"},{"issue":"5","key":"1868_CR21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00005792-197809000-00001","volume":"57","author":"GB Appel","year":"1978","unstructured":"Appel GB, Silva FG, Pirani CL, Meltzer JI, Estes D. Renal involvement in systemic lupud erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine (Baltimore). 1978;57(5):371\u2013410.","journal-title":"Medicine (Baltimore)"},{"key":"1868_CR22","first-page":"857316","volume":"2015","author":"B Satirapoj","year":"2015","unstructured":"Satirapoj B, Tasanavipas P, Supasyndh O. Clinicopathological correlation in asian patients with biopsy-proven lupus nephritis. Int J Nephrol. 2015;2015:857316.","journal-title":"Int J Nephrol"},{"issue":"2","key":"1868_CR23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jcp.39.2.160","volume":"39","author":"P Parichatikanond","year":"1986","unstructured":"Parichatikanond P, Francis ND, Malasit P, Laohapand T, Nimmannit S, Singchoovong L, Nilwarangkur S, Chrirawong P, Vanichakarn S. Lupus nephritis: clinicopathological study of 162 cases in Thailand. J Clin Pathol. 1986;39(2):160\u20136.","journal-title":"J Clin Pathol"},{"issue":"10","key":"1868_CR24","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s10067-010-1517-0","volume":"29","author":"Q Guo","year":"2010","unstructured":"Guo Q, Lu X, Miao L, Wu M, Lu S, Luo P. Analysis of clinical manifestations and pathology of lupus nephritis: a retrospective review of 82 cases. Clin Rheumatol. 2010;29(10):1175\u201380.","journal-title":"Clin Rheumatol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01868-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01868-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01868-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T19:41:47Z","timestamp":1622490107000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01868-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01868-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.20345\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.20345\/v2","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"13 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committees of the Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences (authorization number: Ken 1905\u2013017), and conducted according to the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan. Patient consent was obtained using an opt-out approach.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JW has received speaking honoraria from Astellas, Boehringer Ingelheim, Daiichi Novartis, Sankyo, and Tanabe Mitsubishi, as well as grant support from Astellas, Bayer, Baxter, Chugai, Daiichi Sankyo, Kissei, Kyowa Hakko Kirin, MSD, Novartis, Novo Nordisk, Ono, Otsuka, Pfizer, Teijin, Torii, and Takeda. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}